Andrew Collins, DO
Geriatric Medicine · Owensboro, KYNPI 1568954501
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $862, more than ten times the $26 reported in 2019.
Across 135 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$461
- Amgen$206
- Lilly USA, LLC$181
- Teva Pharmaceuticals USA, Inc.$177
- Novartis$167
- Lundbeck LLC$112
- plus $947 from 18 others
What the payments were for
- Food & beverage$2,23799%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $461 |
| Amgen | 12 | $206 |
| Lilly USA, LLC | 16 | $181 |
| Teva Pharmaceuticals USA, Inc. | 10 | $177 |
| Novartis | 11 | $167 |
| Lundbeck LLC | 6 | $112 |
| GSK | 6 | $105 |
| Otsuka America Pharmaceutical, Inc. | 6 | $104 |
| Sumitomo Pharma America, Inc. | 5 | $91 |
| AstraZeneca | 5 | $72 |
| Exact Sciences | 4 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $64 |
| Boehringer Ingelheim | 4 | $59 |
| AbbVie | 3 | $50 |
| Merck | 3 | $46 |
| Shield Therapeutics Inc | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Pfizer | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$125
How this compares
$2,251 in reported general payments places this provider in the 80th percentile of 33 geriatric medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 188 | $198,952 |
| EliquisApixaban | 185 | $191,335 |
| TrulicityDulaglutide | 81 | $111,226 |
| OzempicSemaglutide | 90 | $104,065 |
| JanuviaSitagliptin Phosphate | 107 | $101,413 |
| FarxigaDapagliflozin Propanediol | 51 | $60,444 |
| MyrbetriqMirabegron | 80 | $49,286 |
| MounjaroTirzepatide | 40 | $44,459 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $35,561 |
| XifaxanRifaximin | 11 | $34,957 |
| XareltoRivaroxaban | 39 | $27,489 |
| LinzessLinaclotide | 26 | $18,808 |
| TradjentaLinagliptin | 18 | $17,165 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $15,335 |
| RybelsusSemaglutide | 13 | $15,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Stiolto Respimat | $59 | $235,696239 claims |
| PfizerEliquis | $33 | $191,335185 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $181 | $155,685121 claims |
| MerckJanuvia, Janumet, Janumet Xr | $46 | $126,789133 claims |
| Novo NordiskOzempic, Rybelsus | $461 | $119,331103 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $72 | $79,48485 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $33 | $61,60391 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $105 | $49,51590 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $64 | $34,95711 claims |
| AbbVieLinzess, Synthroid | $50 | $23,608128 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $91 | $12,51615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 geriatric medicine providers in Kentucky.
Other geriatric medicine in Owensboro
- Azizullah MehrzadOwensboro$3K
- Joseph MitchellOwensboro$949
- Rachel HartLouisville$34K
- Maria AtienzaCorbin$16K
- Josephine GomesLouisville$11K
- Gina D'costaRichmond$4K
- Emmanuel YumangLondon$2K
- Svitlana MandzyLouisville$2K
- Shalini ChhabraMorgantown$2K
- Priyank ChauhanLeitchfield$797
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.